GlassScriptPhysician profile
Christopher W Tomhave
NPI 1558347849
$2,822.27
in general payments reported to CMS, 2019-2025
30 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $391 · 2021: $601 · 2022: $505 · 2023: $187 · 2024: $106 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $389.30 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $287.25 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $273.23 | 2019-2023 | Mounjaro |
| Pfizer INC. | $246.08 | 2019-2025 | |
| Amgen INC. | $242.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $205.00 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $154.18 | 2019-2022 | |
| Allergan, INC. | $150.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $140.44 | 2019-2021 | |
| Abbvie INC. | $115.29 | 2020-2025 | Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.02 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Mylan Specialty L.P. | $91.31 | 2020-2023 | Yupelri |
| Astellas Pharma US INC | $81.70 | 2023-2025 | Veozah |
| Dexcom, INC. | $56.53 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.62 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.27 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.77 | 2022 | |
| Roche Diagnostics Corporation | $24.52 | 2021 | |
| Viatris Specialty LLC | $20.28 | 2025 | Yupelri |
| Ironwood Pharmaceuticals, INC | $19.42 | 2020 | |
| Inspire Medical Systems, INC. | $16.07 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $15.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.59 | 2022 | |
| Esperion Therapeutics, INC. | $12.48 | 2020 | |
| Amarin Pharma, INC. | $12.32 | 2019 | |
| Biogen, INC. | $11.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tomhave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.